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BACKGROUND. Estramustine in combination with other chemotherapeutic agents has dem-
onstrated synergy in hormone-refractory prostate cancer. Docetaxel has demonstrated anti-
neoplastic activity in a variety of chemotherapeutic-unresponsive tumors. We evaluated the
effects of estramustine and docetaxel in preclinical models of prostate cancer.
METHODS. Cell viability of PC-3 and MAT-LyLu (MLL) cells were assessed 48 hr after drug
treatment. For in vivo studies, each flank of five animals in six groups was injected with 1 ×
106 MLL cells: control, estramustine, docetaxel (low- and high-dose), and low- and high-dose
docetaxel with estramustine. Animals were treated on days 4 and 11, and sacrificed on day 14.
RESULTS. The IC50 value for docetaxel was 2 nM in the PC-3 cells and 40 nM in the MLL
cells. The addition of 100 nM of estramustine did not alter the IC50 value for PC-3 cells. In the
MLL cells, however, the IC50 value was lowered to 15 nM. In vivo, low-dose docetaxel with
estramustine demonstrated antineoplastic activity similar to that of high-dose docetaxel
alone, suggesting additive activity between the drugs.
CONCLUSIONS. These results demonstrate that when used in combination, docetaxel and
estramustine can be more effective at lower dosages than when the individual drugs are used
alone. Prostate 44:275–278, 2000. © 2000 Wiley-Liss, Inc.
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INTRODUCTION
Prostate cancer is the most common malignancy di-
agnosed in men, and the second leading cause of
death in American males [1]. There are limited treat-
ment options, and prognosis continues to be dismal in
metastatic hormone-refractory prostate disease. In
newly diagnosed metastatic disease, hormone therapy
controls symptoms in 80–90% of patients . The median
duration of response is approximately 2–3 years. Che-
motherapy is the next option; however, the response
induced by chemotherapy is generally limited and of
short duration, with an overall objective response of
8.7% for single agents and approximately 50% for
newer regimens. Cancer patients are often debilitated
or immunocompromised and, therefore, chemo-
therapy is not always feasible or well-tolerated [2].
Treatment of metastatic disease is considered pallia-
tive, since no chemotherapeutic regimen has shown a
survival benefit in a randomized clinical trial. Due to
these limitations, new agents and strategies clearly
needed.
Estramustine phosphate (Emcyt, Estracyt), a nonni-
trogen mustard carbamate, binds to microtubule-
associated proteins, inhibits assembly, and disrupts
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microtubule organization in vitro [3]. It is this cellular
mechanism, and not the hormonal effect associated
with the estrogen moiety or alkylating activity due to
nitrogen mustard, that is responsible for the cytotoxic
effects of estramustine in hormone-refractory prostate
cancer [3]. Estramustine has also been shown to
reduce the level of serum prostate-specific antigen
(PSA) [4].
Docetaxel (Taxotere), a member of the taxane fam-
ily, binds to tubulin, promoting microtubule assembly
and microtubule bundling [5,6]. Like other members
of the taxane family, docetaxel stabilizes spindle mi-
crotubules, impairing mitosis and blocking progres-
sion through the cell cycle [5]. It demonstrates signifi-
cantly longer cellular affinity and uptake, and slower
cellular efflux than paclitaxel, which prolongs the du-
ration of cell drug exposure [7]. Docetaxel is also ap-
proximately twice as efficient as paclitaxel in stabiliz-
ing microtubules [8].
Estramustine in combination with other chemo-
therapeutic agents has demonstrated synergy in hor-
mone-refractory prostate cancer. Docetaxel has dem-
onstrated antineoplastic activity in a variety of
previously chemotherapeutic-unresponsive tumors.
We here evaluated the in vitro and in vivo effects of






phosphate) was purchased from Hoffmann-LaRoche
(Nutley, NJ). Docetaxel (Taxotere) was purchased
from Rhone-Poulenc Rorer (Collegeville, PA) as a pre-
pared sterile stock solution of 10 mg/ml.
Cell Culture
The prostate adenocarcinoma cell line PC-3 (Ameri-
can Type Culture Collection, Rockville, MD) and the
metastatic MAT-LyLu (MLL) subline of the Dunning
R-3327 rat prostate adenocarcinoma line were grown
and maintained at 37°C in an atmosphere of 5% CO2 in
RPMI-1640 medium (Life Technologies, Grand Island,
NY) containing 1% antibiotic-antimycotic (penicillin
G, 10,000 U/ml; streptomycin sulfate, 10,000 mg/ml;
and amphotericin B, 25 mg/ml) (Life Technologies)
and supplemented with 10% fetal bovine serum (Life
Technologies). Stock drug was added to the cell cul-
ture medium to reach the reported concentrations.
Cell Growth and In Vitro Cytotoxicity Assay
Cell adhesion was used as a marker of cell viability.
At hr 0, 2 × 105 PC-3 and MLL cells, per T25 flask, were
plated in triplicate. At hr 48, increasing doses of doce-
taxel alone, as well as in combination with +100 nM
estramustine, were added to the flasks. After an ad-
ditional 48 hr of incubation, the cells were lysed and
the nuclei counted (Z1 Coulter Counter, Coulter, Hi-
aleah, FL).
Animals
Male Copenhagen rats were obtained from Harlan
Sprague-Dawley (Indianapolis, IN). Methoxyflurane
(Pittman-Moore, Washington Crossing, NJ) was used
as inhalation anesthetic for injections and surgical pro-
cedures.
In Vivo Animal Tumor Model
Animals, 5 per group, were injected with 1 × 106
MLL cells subcutaneously into each flank on day 0.
There were 5 rats per treatment and control group,
respectively.
Treatment groups consisted of the following: 1)
control, 2) estramustine (7 mg/kg), 3) low-dose doce-
taxel (7 mg/kg), 4) high-dose docetaxel (11.6 mg/kg),
5) low-dose docetaxel and estramustine, and 6) high-
dose docetaxel and estramustine.
On day 0, animals were injected with 1 × 106 MLL
cells in each flank. On days 4 and 11, animals were
given intraperitoneal injections of the drugs. On day
14, animals were sacrificed, the tumors were har-
vested, and the tumor weights were noted. Paired Stu-
dent’s t-test was used to compare control and treat-
ment groups.
Fig. 1. In vitro analysis of PC-3 cells treated with Taxotere
demonstrated an IC50 value of approximately 2 nM. The addition
of Emcyt (100 nM) did not significantly alter this IC50 value.
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RESULTS
In Vivo Cytotoxicity Experiments
The human prostate cancer cell line PC-3 and the
Dunning rat R2237 metastatic anaplastic to lymph
node, lung (MLL) subline were tested for sensitivity to
docetaxel and estramustine in combination. The IC50
for docetaxel was approximately 2 nM for PC-3 cells
(Fig. 1). The addition of 100 nM of estramustine did
not significantly alter the IC50 for any docetaxel dose.
In MLL cells, the IC50 was approximately 40 nM (Fig.
2). The addition of 100 nM of estramustine lowered
the IC50 of docetaxel to approximately 15 nM.
In Vivo Animal Model
Copenhagen rats were injected with 1 × 106 MLL
cells into each flank on day 0. Rats were treated intra-
peritoneally on days 4 and 11, and then sacrificed on
day 14. There was a significant decrease (>50%) in
tumor weight in mice treated with high dose docetaxel
(Fig. 3). This was even more prominent in both low-
dose docetaxel and high-dose docetaxel in combina-
tion with estramustine (100 nM). Clinically, decreased
clearance of docetaxel was associated with estramus-
tine combinations. However, clearance data were not
obtained in this study.
DISCUSSION
The evaluation of new agents and combination
therapies in metastatic prostate cancer has led to the
realization of increased response rates due to syner-
gism involving different mechanisms of action of vari-
ous chemotherapy drugs on a related pathway (e.g.,
DNA synthesis, antimetabolites, cell adhesion). Re-
duction in the required dosages of individual drugs
and potentially decreased toxic side effects is another
advantage of using these combination therapies.
Estramustine has been shown to bind to microtu-
bule-associated proteins and disrupt microtubule or-
ganization in vitro [9,10]. Estramustine is currently in-
dicated in the palliative treatment of patients with
metastatic and/or progressive prostate cancer, with a
response rate of 5–17% as a single agent [11]. Its tox-
icities include fluid overload and thrombophlebitis.
Docetaxel, a semisynthetic taxoid, interferes with
the microtubular network essential for mitotic and in-
terphase cellular functions [12,13]. It binds to free tu-
bulin and promotes the assembly of stable microtu-
bules that cannot disassemble [12]. As a single agent,
it has been shown to be effective in chemoresistant
breast cancer [14]. Bone marrow suppression is a ma-
jor dose-limiting toxicity.
Combining agents that are active against a particu-
lar tumor but do not have overlapping toxicities has
been a basic rule in clinical oncology. In patients with
prostate cancer, this has not been the case. Preclinical
studies demonstrated that a single-agent estramustine
(noneffective as a single agent) and docetaxel (nonef-
fective as a single agent) demonstrated synergistic ac-
tivity, and the combination of the two agents was
clinically much more effective than when either agent
was given alone [15].
A phase I trial evaluated Emcyt and Taxotere [16].
The regimen consisted of Emcyt 280 mg PO TID days
1–5, Taxotere 40, 60, or 70 mg/m2, and Decadron 20
mg 6 + 12 hr, and 15 min prior to Taxotere on day 2.
The cycle was repeated every 21 days. The overall
response rate was 62%, as defined by a PSA decrease
of at least 50%. Of the responders, 69% failed steroids
and 54% failed Emcyt. Forty-three percent of patients
with measurable disease had a partial response. The
Fig. 2. MLL cells treated with Taxotere in vitro had an
IC50 value of 40 nM. The addition of Emcyt (100 nM) low-
ered this value to approximately 15 nM.
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toxicities included fluid retention, granulocytopenia,
and hepatotoxicity.
Another phase I/II trial by Kreis in 1999 [15] again
involved Emcyt and Taxotere. The regimen consisted
of Emcyt 140 mg/10 kg body weight PO QD, Taxotere
40, 60, or 80 mg/m2, and Decadron 8 mg BID × 5
doses. The cycle was repeated every 21 days. Nine
patients in total were enrolled. Four patients had at
least a 50% decrease in PSA. The toxicities included
esophageal dyspepsia, nausea, and diarrhea.
Our results demonstrate that docetaxel and estra-
mustine have a significant cytotoxic effect in the PC-3
and MAT-LyLu prostatic cell lines. We demonstrated
enhanced cytotoxic effects when these drugs were
used in combination, both in vitro and in vivo, with
MLL cells. These results are similar to those reported
by other authors using combinations of these agents.
CONCLUSIONS
In vitro, docetaxel has significant cytotoxic activity.
This effect was also demonstrated in vivo in this
study. The addition of estramustine did not enhance
this effect in vitro in the PC-3 cell line, but was sig-
nificant in MLL cells. In vivo studies demonstrated a
significant decrease in tumor weight of mice treated
with either low- or high-dose docetaxel in combina-
tion with estramustine.
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Fig. 3. In vivo study, demonstrating a decrease in tumor mass of
mice treated with Taxotere (11.6 mg/kg) alone. The addition of
Emcyt (100 nM) significantly lowered the tumor mass in mice
treated with low-dose Taxotere (7 mg/kg), but not high-dose
Taxotere (11.6 mg/kg), suggesting an additive effect in the latter.
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